Close Menu

More articles about Infectious Disease

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

The assays are performed on nasal swab specimens self-collected by patients under the observation of a healthcare provider via telemedicine. 

Significant revenue from molecular and rapid diagnostic testing for SARS-CoV-2 offset declines in core lab volumes.

The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.

The firm's various COVID-19 molecular test offerings offset declines in core laboratory and point-of-care segments.

KogeneBiotech and Trax Management's tests may be performed by any CLIA-certified high-complexity lab, while the Compass test may only be performed by its developer.

The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.

The firm said it expects FDA clearance for its Acuitas AMR Gene Panel, although it has been delayed due to the agency's extended review timelines.

The population genomics firm said that it can provide 2,000 COVID-19 PCR tests per day out of its San Diego lab while it awaits FDA Emergency Use Authorization.

Researchers from South Korea used 10x Genomics' scRNA-seq platform to also find type I IFN-driven inflammatory features in patients with severe influenza.

The company said it has signed a US distribution agreement for its COVID-19 test with an undisclosed strategic partner.

Vela Diagnostics said that the RT-PCR-based test has also received provisional authorization from the Health Sciences Authority in Singapore.

OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.

Users will be able to sequence over 20,000 samples simultaneously with the updated panel, which the firm expects to offer sometime in the third quarter for research use only. 

UCSF's test, developed with Mammoth Biosciences, uses CRISPR technology, while the tests from the Broad Institute and BioSewoom are PCR-based.

Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.

A handful of researchers and companies are hoping to finally bring the paper-based molecular diagnostic space to fruition.

The better-than-expected sales growth reflects "very significant demand" for COVID-19 testing products, tempered by weaker customer demand in other product areas.

The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.

The Enzo and Access Bio tests may be performed by any CLIA-certified high complexity lab, while use of Gene By Gene's test is limited to its developer.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.